CN107250149A - 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 - Google Patents
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 Download PDFInfo
- Publication number
- CN107250149A CN107250149A CN201680010388.0A CN201680010388A CN107250149A CN 107250149 A CN107250149 A CN 107250149A CN 201680010388 A CN201680010388 A CN 201680010388A CN 107250149 A CN107250149 A CN 107250149A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- deuterium
- acid
- gallbladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/007—Steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物。具体地,本发明公开了式(I)所示的氘代鹅去氧胆酸衍生物以及含有该化合物、或其晶型、药学上可接受的盐、水合物或溶剂合物的药物组合物。本发明的上述化合物可用于治疗和/或预防非酒精性脂肪肝炎、非酒精性脂肪肝病、胆结石、原发性胆汁性肝硬化、肝硬化等。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015100847385 | 2015-02-16 | ||
CN201510084738.5A CN105985396A (zh) | 2015-02-16 | 2015-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
PCT/CN2016/073891 WO2016131414A1 (zh) | 2015-02-16 | 2016-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107250149A true CN107250149A (zh) | 2017-10-13 |
CN107250149B CN107250149B (zh) | 2020-11-24 |
Family
ID=56692502
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510084738.5A Pending CN105985396A (zh) | 2015-02-16 | 2015-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
CN201680010388.0A Active CN107250149B (zh) | 2015-02-16 | 2016-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510084738.5A Pending CN105985396A (zh) | 2015-02-16 | 2015-02-16 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10544185B2 (zh) |
EP (1) | EP3260463B1 (zh) |
JP (1) | JP6947644B2 (zh) |
KR (1) | KR102042112B1 (zh) |
CN (2) | CN105985396A (zh) |
AU (1) | AU2016222174B2 (zh) |
BR (1) | BR112017017529A2 (zh) |
CA (1) | CA2977109C (zh) |
HK (1) | HK1248712A1 (zh) |
RU (1) | RU2712033C2 (zh) |
WO (1) | WO2016131414A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
SI2986623T1 (sl) | 2013-04-17 | 2019-03-29 | Sage Therapeutics, Inc. | 19-NOR C3,3-disubstituirani C21-N-pirazolil steroidi in metode njhove uporabe |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
DK3021852T3 (da) | 2013-07-19 | 2021-03-15 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
SG10202009859YA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
JP6745274B2 (ja) | 2015-01-26 | 2020-08-26 | セージ セラピューティクス, インコーポレイテッド | Cns障害を処置するための組成物および方法 |
EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN106008639B (zh) * | 2016-03-11 | 2019-01-08 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
DK3481844T3 (da) | 2016-07-11 | 2024-07-22 | Sage Therapeutics Inc | C7, C12 og C16 substituerede neuroaktive steroider og disses fremgangsmåder til anvendelse |
BR112020001362A2 (pt) | 2017-07-24 | 2020-08-11 | Intercept Pharmaceuticals, Inc. | derivados de ácido biliar isotopicamente marcados |
KR20200096596A (ko) * | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
TW202021595A (zh) | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
CN112142814B (zh) * | 2019-06-26 | 2021-09-28 | 江苏吉贝尔药业股份有限公司 | 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂 |
JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
CN112409435B (zh) * | 2019-08-23 | 2023-07-18 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
CA3159163A1 (en) | 2020-01-15 | 2021-07-22 | Raphael Darteil | Use of fxr agonists for treating an infection by hepatitis d virus |
MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強 |
KR102490355B1 (ko) * | 2021-09-29 | 2023-01-26 | 주식회사 에이.비.아이 | 타우로케노디옥시콜산 함량이 증대된 담즙 추출물을 유효성분으로 포함하는 비만증 예방, 개선 또는 치료용 조성물 및 그의 제조방법 |
WO2024043842A1 (en) * | 2022-08-22 | 2024-02-29 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients |
WO2024144482A1 (en) * | 2022-12-30 | 2024-07-04 | Humanis Saglik Anonim Sirketi | Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
WO2005082925A2 (en) * | 2004-02-26 | 2005-09-09 | Intercept Pharmaceuticals Inc. | Novel steroid agonist for fxr |
WO2010054158A2 (en) * | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
WO2013192097A1 (en) * | 2012-06-19 | 2013-12-27 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3696884B2 (ja) * | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
US6376531B1 (en) * | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
ES2193921T3 (es) * | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
ES2774368T3 (es) | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos de uso de los mismos |
CN104370990A (zh) * | 2008-11-19 | 2015-02-25 | 英特塞普特医药品公司 | G蛋白偶联受体5(tgr5)调节剂及其使用方法 |
WO2013037482A1 (en) * | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
WO2015061421A1 (en) * | 2013-10-22 | 2015-04-30 | Metselex, Inc. | Deuterated bile acids |
-
2015
- 2015-02-16 CN CN201510084738.5A patent/CN105985396A/zh active Pending
-
2016
- 2016-02-16 KR KR1020177025774A patent/KR102042112B1/ko active IP Right Grant
- 2016-02-16 CA CA2977109A patent/CA2977109C/en active Active
- 2016-02-16 CN CN201680010388.0A patent/CN107250149B/zh active Active
- 2016-02-16 WO PCT/CN2016/073891 patent/WO2016131414A1/zh active Application Filing
- 2016-02-16 BR BR112017017529-0A patent/BR112017017529A2/zh active Search and Examination
- 2016-02-16 US US15/551,224 patent/US10544185B2/en active Active
- 2016-02-16 EP EP16751945.3A patent/EP3260463B1/en active Active
- 2016-02-16 AU AU2016222174A patent/AU2016222174B2/en active Active
- 2016-02-16 RU RU2017130849A patent/RU2712033C2/ru active
- 2016-02-16 JP JP2017560864A patent/JP6947644B2/ja active Active
-
2018
- 2018-06-26 HK HK18108236.7A patent/HK1248712A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072598A1 (en) * | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
WO2005082925A2 (en) * | 2004-02-26 | 2005-09-09 | Intercept Pharmaceuticals Inc. | Novel steroid agonist for fxr |
WO2010054158A2 (en) * | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
WO2013192097A1 (en) * | 2012-06-19 | 2013-12-27 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
Non-Patent Citations (1)
Title |
---|
江文峰 等: "氘代作用在药物研究中的应用", 《齐鲁药事》 * |
Also Published As
Publication number | Publication date |
---|---|
RU2017130849A (ru) | 2019-03-18 |
HK1248712A1 (zh) | 2018-10-19 |
KR20170110723A (ko) | 2017-10-11 |
CA2977109C (en) | 2020-04-14 |
RU2712033C2 (ru) | 2020-01-24 |
EP3260463A4 (en) | 2018-10-31 |
EP3260463A1 (en) | 2017-12-27 |
RU2017130849A3 (zh) | 2019-03-18 |
CA2977109A1 (en) | 2016-08-25 |
WO2016131414A1 (zh) | 2016-08-25 |
BR112017017529A2 (zh) | 2018-04-17 |
AU2016222174A1 (en) | 2017-09-14 |
US10544185B2 (en) | 2020-01-28 |
AU2016222174B2 (en) | 2019-04-11 |
CN107250149B (zh) | 2020-11-24 |
JP6947644B2 (ja) | 2021-10-13 |
EP3260463B1 (en) | 2020-09-02 |
US20180030083A1 (en) | 2018-02-01 |
CN105985396A (zh) | 2016-10-05 |
JP2018505220A (ja) | 2018-02-22 |
KR102042112B1 (ko) | 2019-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107250149A (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
CN111295372B (zh) | 硝羟喹啉前药及其用途 | |
CN100384830C (zh) | 环黄芪醇类衍生物以及用途 | |
TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
EP2947070A1 (en) | Multi-targeted ubenimex prodrug derivative and preparation method and use thereof | |
US8435962B2 (en) | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | |
EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
WO2013000286A1 (zh) | 蟾毒配基衍生物及其制备方法、包含该衍生物的组合物、及其用途 | |
CN101289438B (zh) | 3-(3'-羟基)-丁基苯酞酯及其制法和用途 | |
WO2020114495A1 (zh) | 二核苷酸化合物及其前体药物 | |
KR20200119786A (ko) | 간 전달 엔테카비어 프로드러그 뉴클레오티드 시클로 포스페이트 화합물 및 응용 | |
CN110088098A (zh) | 喹唑啉酮类parp-1抑制剂及其制备方法、药物组合物和用途 | |
CN103304573B (zh) | 石蒜碱类化合物在制备抗肿瘤药物的应用 | |
CN116178350A (zh) | 一种天然来源大环内酯衍生物及其制备方法和作为抗肿瘤药物的应用 | |
CN111518157B (zh) | 一种雷公藤甲素衍生物及其制备方法和应用 | |
CN113214207B (zh) | 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途 | |
US20200317711A1 (en) | Cytarabine prodrug nucleoside cyclic phosphate compound based on liverspecific delivery and use | |
EP3470403B1 (en) | Taxoid compound and preparation method and use thereof | |
CN113214206B (zh) | 橙皮素与甜菜碱共晶物b及制备方法和其组合物与用途 | |
AU2022100062A4 (en) | Crystal form for treating liver disease and use thereof | |
CN116003469B (zh) | 嘧啶基抗病毒化合物的制备与使用方法 | |
WO2021033766A1 (ja) | ビタミンd活性を有するリトコール酸誘導体 | |
CN105949277B (zh) | 一种抗肿瘤化合物及其用途 | |
KR20240055039A (ko) | Ampk 활성화제로서 유용한 티아디아졸론 유도체 | |
CN108640958A (zh) | 异苯并呋喃衍生物、其药物组合物和制剂以及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 215300 Chenfeng Road 209, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Applicant after: Suzhou Zehuang Biopharmaceutical Co., Ltd. Address before: 215300 Chenfeng Road 209, Kunshan City, Suzhou City, Jiangsu Province Applicant before: Suzhou Zelgen Biopharmaceuticals Co., Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |